Back to Insights

What challenges could Biogen’s Aduhelm (aducanumab) face as it goes to market?

Posted by Varun Renjen, M.D. on June 28th, 2021.

Biogen’s Aduhelm® (aducanumab) is the fist potentially disease-modifying therapy approved for Alzheimer’s disease.  However, it could face some significant challenges as it goes to market.

Varun Renjen, M.D., describes the three main ones in this short video.

Link here.